Victory Capital Management Inc. Acquires 21,764 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Victory Capital Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,928,715 shares of the company’s stock after acquiring an additional 21,764 shares during the quarter. Victory Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $34,755,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TEVA. New Covenant Trust Company N.A. purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $30,000. UMB Bank n.a. increased its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $48,000. Finally, Byrne Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $52,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.9 %

NYSE:TEVA opened at $16.43 on Friday. The firm has a market capitalization of $18.61 billion, a P/E ratio of -19.33, a P/E/G ratio of 1.32 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 52 week low of $8.64 and a 52 week high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The company has a fifty day moving average of $17.78 and a 200 day moving average of $17.22.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. Barclays upped their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.